RxSight, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 07, 2023 at 04:17 pm EDT
Share
RxSight, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 20.81 million compared to USD 11.36 million a year ago. Net loss was USD 13.8 million compared to USD 16.73 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.61 a year ago.
For the six months, sales was USD 38.3 million compared to USD 20.3 million a year ago. Net loss was USD 27.02 million compared to USD 34.33 million a year ago. Basic loss per share from continuing operations was USD 0.82 compared to USD 1.25 a year ago.
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Companyâs RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patientâs vision outcomes.
RXSIGHT, INC. 
